Lung-Ji Chang
Shenzhen Geno-Immune Medical Institute · Shenzhen Genoimmune Medical Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lung-Ji Chang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:44 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04299724 · Safety and Immunity of Covid-19 aAPC VaccineShenzhen Geno-Immune Medical Institute · terminated · Treat and Prevent Covid-19 Infection · principal investigator
- Ph1/Ph2NCT04276896 · Immunity and Safety of Covid-19 Synthetic Minigene VaccineShenzhen Geno-Immune Medical Institute · terminated · Pathogen Infection Covid-19 Infection · principal investigator
- Ph1/Ph2NCT04016129 · CAR-T Immunotherapy Targeting CD19- ALLShenzhen Geno-Immune Medical Institute · not yet recruiting · B-cell Leukemia · principal investigator
- Ph1/Ph2NCT04010877 · Multiple CAR-T Cell Therapy Targeting AMLShenzhen Geno-Immune Medical Institute · terminated · Acute Myeloid Leukemia · principal investigator
- Ph1NCT03961243 · Lentiviral FIX Gene TherapyShenzhen Geno-Immune Medical Institute · not yet recruiting · Hemophilia B · principal investigator
- Ph1NCT03914768 · Immune Modulatory DC Vaccine Against Brain TumorShenzhen Geno-Immune Medical Institute · not yet recruiting · Diffuse Intrinsic Pontine Glioma or Glioblastoma · principal investigator
- N/ANCT03725670 · Direct Lentiviral Injection Gene Therapy for MLDShenzhen Geno-Immune Medical Institute · not yet recruiting · Metachromatic Leukodystrophy (MLD) · principal investigator
- N/ANCT03645460 · Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA)Shenzhen Geno-Immune Medical Institute · not yet recruiting · Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID) · principal investigator
- Ph1/Ph2NCT03614650 · Immunotherapy Treating GI CancerShenzhen Geno-Immune Medical Institute · not yet recruiting · Cancer · study chair
- Ph1/Ph2NCT03362619 · Engineered Immune Effectors Against Cervical CancerShenzhen Geno-Immune Medical Institute · terminated · Cervical Cancer · principal investigator
- Ph1/Ph2NCT03362606 · Engineered Immune Effectors Against Ovarian CancerShenzhen Geno-Immune Medical Institute · terminated · Ovarian Cancer · principal investigator
- Ph1/Ph2NCT03356782 · Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting SarcomasShenzhen Geno-Immune Medical Institute · not yet recruiting · Sarcoma, Osteoid Sarcoma, Ewing Sarcoma · principal investigator
- Ph1/Ph2NCT03356795 · Intervention of CAR-T Against Cervical CancerShenzhen Geno-Immune Medical Institute · terminated · Cervical Cancer · principal investigator
- Ph1/Ph2NCT03356808 · Antigen-specific T Cells Against Lung CancerShenzhen Geno-Immune Medical Institute · not yet recruiting · Lung Cancer · principal investigator
- Ph1/Ph2NCT03353428 · Intervention of Engineered Immune Effector T Cells Against Lung CancerShenzhen Geno-Immune Medical Institute · withdrawn · Lung Cancer, NSCLC · principal investigator
- Ph1/Ph2NCT03351855 · HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPVShenzhen Geno-Immune Medical Institute · terminated · Human Papilloma Virus · principal investigator
- N/ANCT03351868 · FANCA Gene Transfer for Fanconi Anemia Using a High-safety, High-efficiency, Self-inactivating Lentiviral VectorShenzhen Geno-Immune Medical Institute · terminated · Fanconi Anemia · principal investigator
- N/ANCT03351829 · Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral VectorShenzhen Geno-Immune Medical Institute · not yet recruiting · Beta-Thalassemia · principal investigator
- Ph1/Ph2NCT03271632 · Multi-CAR T Cell Therapy in the Treatment of Multiple MyelomaShenzhen Geno-Immune Medical Institute · not yet recruiting · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT03222674 · Multi-CAR T Cell Therapy for Acute Myeloid LeukemiaShenzhen Geno-Immune Medical Institute · not yet recruiting · Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT03217617 · SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) InjectionShenzhen Geno-Immune Medical Institute · not yet recruiting · SCID, X-Linked · principal investigator
- Ph1NCT03217032 · Lentiviral FVIII Gene TherapyShenzhen Geno-Immune Medical Institute · not yet recruiting · Hemophilia A · principal investigator
- Ph1/Ph2NCT03184753 · Genetically Modified T Cells Against Ovarian CancerShenzhen Geno-Immune Medical Institute · terminated · Ovarian Cancer · principal investigator
- Ph1/Ph2NCT03185468 · Intervention of Bladder Cancer by CAR-TShenzhen Geno-Immune Medical Institute · terminated · Bladder Cancer, Urothelial Carcinoma Bladder · principal investigator
- Ph1NCT03170141 · Immunogene-modified T (IgT) Cells Against Glioblastoma MultiformeShenzhen Geno-Immune Medical Institute · terminated · Glioblastoma Multiforme of Brain, Brain Cancer · principal investigator
- Ph1/Ph2NCT03159364 · Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic InfectionsShenzhen Geno-Immune Medical Institute · terminated · Pathogen Infection, EBV Infection, CMV Infection · principal investigator
- Ph1/Ph2NCT03125577 · Combination CAR-T Cell Therapy Targeting Hematological MalignanciesShenzhen Geno-Immune Medical Institute · terminated · B-cell Malignancies · principal investigator
- Ph1/Ph2NCT03098355 · Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell MalignanciesZhujiang Hospital · withdrawn · B-Cell Leukemia, B-Cell Lymphoma · study director
- N/ANCT03050190 · A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell MalignanciesShenzhen Geno-Immune Medical Institute · terminated · B-cell Malignancies · principal investigator
- Ph1/Ph2NCT02992210 · Study on GD2 Positive Solid Tumors by 4SCAR-GD2Shenzhen Geno-Immune Medical Institute · not yet recruiting · Solid Tumor · principal investigator
- Ph1NCT02765243 · Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent NeuroblastomaZhujiang Hospital · completed · Neuroblastoma, Effects of Immunotherapy · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:44 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in osteosarcoma.